Streetbeat News

Products Services

TOVX

Theriva Biologics has been granted an EU patent (#3292142) for its innovative approach to cancer treatment using oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes. This patent represents a significant advancement in the field of cancer therapy, potentially offering new treatment options for patients.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 8:01 pm

NVDA

SPRX

NVIDIA Corporation (NVDA) remained stable as the S&P 500 rose, following the Federal Reserve's decision to hold rates steady. Nvidia has seen significant growth, up 148% from Oct. 31 to March 8, driven by bullish sentiment in the AI market. At its GTC Conference, Nvidia unveiled its new GPU architecture, Blackwell. Nvidia's stock has formed a bull flag pattern, suggesting potential upward movement. The Spear Alpha ETF (SPRX), which includes Nvidia as a major holding, offers diversification for investors looking to capitalize on Nvidia's momentum.

Portfolio Pulse from Melanie Schaffer

March 20, 2024 | 7:28 pm

REGN

Regeneron Pharmaceuticals (NASDAQ:REGN) has seen unusual options activity, with a bullish sentiment from deep-pocketed investors. The activity includes 10 extraordinary options trades, with 60% bullish and 40% bearish sentiment. The focus is on a price band between $900.0 and $1020.0. The company, known for its products in eye disease, cardiovascular disease, cancer, and inflammation, has a current stock price of $966.07, up 0.25%. Analysts have given an average target price of $1137.25, with varying ratings from Outperform to Overweight.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 7:16 pm

BTCUSD

Ali Martinez, a technical and on-chain analyst, shared a dollar-cost averaging (DCA) strategy for Bitcoin investment on X (formerly Twitter). The strategy involves buying a fixed amount of Bitcoin at regular intervals, aiming to reduce the impact of market volatility. Martinez outlined steps for implementing this strategy and suggested specific buying points for Bitcoin based on its price. This approach is designed for long-term profitability despite potential short-term price pullbacks.

Portfolio Pulse from Khyathi Dalal

March 20, 2024 | 7:13 pm

RIO

Rio Tinto (NYSE:RIO) announced a $350 million investment in its Rincon lithium project in Argentina, aiming to expand the plant and support the EV market with high-quality lithium. This move highlights Argentina's growing role in the global lithium market, with the country's production increasing by 45% from 2022 to 2023. The Rincon project, part of the lithium-rich Salta province, aims for first lithium production by year's end, aligning with Rio Tinto's decarbonization goals.

Portfolio Pulse from Stjepan Kalinic

March 20, 2024 | 6:53 pm

CMPS

CYBN

MNMD

PSIL

Cybin Inc. received FDA Breakthrough Therapy designation for its psilocybin therapy for Major Depressive Disorder, alongside positive clinical data and a $150M private placement. MindMed also received the designation for its LSD-derived treatment for Generalized Anxiety Disorder, with expected proceeds of $175M from share offerings. Gilgamesh Pharmaceuticals was awarded a $14M grant for ibogaine analog research. Psyence Biomedical, Red Light Holland, and Clearmind Medicine were mentioned for their developments in psychedelics. The article also covered stock performances of several psychedelics companies.

Portfolio Pulse from Lara Goldstein

March 20, 2024 | 6:49 pm

DXCM

Benzinga's options scanner revealed significant trading activity on DexCom (NASDAQ:DXCM) options, with a focus on a price range of $97.5 to $131.0. The analysis of options trades, including both calls and puts, suggests a bullish sentiment among investors. DexCom, a company specializing in continuous glucose monitoring systems, has seen its stock price increase by 0.4% to $134.7. Analysts have set an average target price of $165.0 for DexCom, with RBC Capital downgrading its rating to Outperform.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 6:45 pm

NFLX

The options market shows a bearish sentiment towards Netflix (NASDAQ:NFLX), with 63% of trades being bearish. Major market movers are targeting a price range between $5.0 and $1100.0 for Netflix. Significant options trades have been detected, including both bearish and bullish positions. Netflix's business model focuses on its streaming service, with a global subscriber base of almost 250 million. The stock is currently down -0.15% at $619.81, with analysts setting an average price target of $694.0.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 6:45 pm

DHI

HD

LEN

LOW

The U.S. housing market is experiencing a mortgage lock-in issue, where high mortgage rates discourage homeowners from selling, contributing to a housing shortage and pushing prices up. Home development retailers like Home Depot Inc (HD) and Lowe's Companies Inc (LOW) have seen sales boosts due to homeowners opting to improve their current homes instead of moving. This situation pressures builders like D.R. Horton Inc (DHI) and Lennar Corporation (LEN) to increase new home construction. The Federal Housing Finance Agency reports that mortgage lock-in reduced home sales by 57% in Q4 2023, suggesting solutions like tax credits and mortgage portability to alleviate the issue.

Portfolio Pulse from Neil Dennis

March 20, 2024 | 6:29 pm

IGC

IGC Pharma (NYSE:IGC) announced promising interim results for their Alzheimer's drug, IGC-AD1, at Benzinga's Healthcare Summit. The drug, aimed at reducing agitation in Alzheimer's patients, shows potential in addressing both neuropsychiatric symptoms and the disease's underlying pathology by reducing amyloid plaques. IGC-AD1 demonstrated rapid effectiveness within two weeks and a favorable safety profile. The news led to a temporary trading halt of IGC's shares, underscoring market anticipation for this innovative treatment.

Portfolio Pulse from Abbey Higginbotham

March 20, 2024 | 6:02 pm